Hemangioma is a common benign tumor in infants and children, mostly appearing at birth or within a few weeks after birth. Hemangiomas are divided into vascular tumors and vascular malformations. The former are superficial hemangiomas (known as “strawberry hemangiomas” in the past), deep hemangiomas, and mixed hemangiomas due to abnormal proliferation of vascular endothelial cells. The latter is a developmental malformation based on the vascular-based vascular system, commonly known as erythematous nevus. The pathogenesis and mechanisms are unknown. The proliferative phase of hemangioma appears between 6 months and 1 year after birth, after which it enters the regressive phase. About 40% of superficial hemangiomas leave permanent marks such as scarring, atrophy, and skin color change after regression. Complications of hemangiomas include bleeding, ulceration, infection, and compression and functional effects of hemangiomas on vital organs. Vivid nevus gradually increases in color with age, especially on the face, and the lesions gradually thicken and appear as plaques and nodules. The aesthetic impact may cause psychological shadow to the affected children. Therefore, early treatment of hemangioma is necessary, and some early treatment of hemangioma can achieve very good results. The choice of clinical treatment for infantile hemangioma depends on the depth, scope and size of the lesion and whether there is any functional disorder. The current treatment methods for hemangioma include laser therapy, oral medication, surgical excision, injection therapy, cryotherapy, radiation and radionuclide therapy. The principle of laser treatment is based on the selective photothermal effect of laser, which causes the oxygenated hemoglobin in blood to absorb light energy and generate heat, and the red blood cells are destroyed to form thrombus, resulting in vascular damage, thus achieving the purpose of treating hemangioma. The safety and effectiveness of laser treatment for cutaneous hemangioma are relatively high. Clear diagnosis and treatment of hemangioma in children should be done as early as possible and at the right time, especially during the proliferation phase. This can not only stop the growth of hemangioma, prevent spontaneous ulceration and damage to vital organs, but also promote the early regression of hemangioma, and accelerate the regression of those already in the regression phase. The superiority of early treatment is to achieve the best possible regression or improvement.